Innoviva Inc
XMUN:HVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innoviva Inc
XMUN:HVE
|
US |
|
Keel Infrastructure Corp
F:9MK
|
US |
|
DGR Global Ltd
F:D4A
|
AU |
Intrinsic Value
The intrinsic value of 
Innoviva Inc (HVE) under the Base Case is 9.592 EUR per share.
Compared with the current market price of 9.219 EUR, the stock appears
Undervalued by 4% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Innoviva Does
Innoviva is a healthcare royalty company. Its main business is owning rights to receive payments on medicines developed and sold by other companies, especially inhaled treatments for lung diseases. Instead of running a big drug sales force, Innoviva sits further up the value chain and collects income when partner products sell well.
- Headquarters
- United States of America US
- Employees
- 159
- IPO date
- Oct 5, 2004
Revenue & Expenses Breakdown
Innoviva Inc
Earnings Waterfall
Innoviva Inc
The intrinsic value for Innoviva Inc (HVE) under the Base Case is 9.592 EUR.
Compared with the current market price of 9.219 EUR, the stock appears Undervalued by 4% .